Oslo Cancer Cluster member Nordic Nanovector`s lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC).
Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as commercial exclusivity for ten years once the product reaches the market in Europe.
Jan A. Alfheim, Nordic Nanovector CEO stated: “With the orphan designation for Betalutin™ in the Europe, the company can receive protocol assistance, a type of scientific advice specific for designated orphan medicines and market exclusivity once the medicine is on the market. Fee reductions are also available. These benefits will help tremendously in the development and commercialization of an important new form of treatment of non-Hodgkin Lymphoma“.
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).